Table 2. Descriptive statistics by UROMOL signature classification.
Data are presented as mean (SD) or n (%).
| 1/ Luminal n = 26 | 2/ Luminal CIS-like n = 28 | 3/ Early basal-like n = 24 | p | |
|---|---|---|---|---|
|
| ||||
| Institution/cohort | 0.08 | |||
| UNC | 7 (26.9%) | 8 (28.6%) | 13 (54.2%) | |
| MSK | 19 (73.1%) | 20 (71.4%) | 11 (45.8%) | |
|
| ||||
| Age (years) | 61.6 (14.9) | 65.3 (11.2) | 68.3 (10.3) | 0.159 |
|
| ||||
| Male sex | 20 (76.9%) | 20 (71.4%) | 19 (79.2%) | 0.797 |
|
| ||||
| Stage | 0.001 | |||
| T1 | 4 (15.4%) | 15 (53.6%) | 16 (66.7%) | |
| Ta | 22 (84.6%) | 13 (46.4%) | 8 (33.3%) | |
|
| ||||
| Grade 1 | < 0.001 | |||
| High | 12 (46.2%) | 27 (96.4%) | 21 (87.5%) | |
| Low | 14 (53.8%) | 0 (0.00%) | 2 (8.33%) | |
|
| ||||
| Carcinoma in situ | 8 (30.8%) | 2 (7.14%) | 7 (29.2%) | 0.063 |
|
| ||||
| Tumor cellularity 1 | 0.004 | |||
| 0–40 | 6 (23.1%) | 11 (40.7%) | 16 (69.6%) | |
| 50–90 | 20 (76.9%) | 16 (59.3%) | 7 (30.4%) | |
1
Missing values omitted
CIS = carcinoma in situ; MSK = Memorial Sloan Kettering Cancer Center; SD = standard deviation; UNC = University of North Carolina.